VA
HOWL icon

Verdad Advisers’s Werewolf Therapeutics HOWL Stock Holding History

Verdad Advisers’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.8K Buy
+29,760
New +$20.4K 0.03% 177

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Verdad Advisers's HOWL Position: Q1 2026 in Review

Verdad Advisers opened a new position in Werewolf Therapeutics (HOWL) in Q1 2026: 29,760 shares worth $24.8K. The stake represents 0.03% of the portfolio and ranks #177 among its holdings.

48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Verdad Advisers held 29,760 shares of Werewolf Therapeutics worth $24.8K as of Q1 2026.
  • Werewolf Therapeutics was a new Verdad Advisers position in Q1 2026.
  • Werewolf Therapeutics made up 0.03% of Verdad Advisers's portfolio in Q1 2026, its #177 holding.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.